Singapore’s Tikva targets solid cancer barrier with US$8M Series A

For years, cell therapy has carried one of oncology’s most striking contradictions. It has changed the outlook for some blood cancer patients, yet has struggled to make the same impact in solid tumours, which account for the vast majority of cancer cases worldwide. Singapore-based Tikva Allocell is trying to push through that wall with a [] The post Singapores Tikva targets solid cancer barrier with US$8M Series A appeared first on e27 .